Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) EBT Margin (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed EBT Margin for 6 consecutive years, with 79.61% as the latest value for Q3 2025.

  • On a quarterly basis, EBT Margin fell 1184.0% to 79.61% in Q3 2025 year-over-year; TTM through Sep 2025 was 98.77%, a 1229.0% decrease, with the full-year FY2024 number at 74.09%, up 2465.0% from a year prior.
  • EBT Margin was 79.61% for Q3 2025 at Vivos Therapeutics, up from 131.23% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 452.05% in Q4 2022 to a low of 168.67% in Q4 2021.
  • A 5-year average of 79.48% and a median of 110.06% in 2024 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: soared 62072bps in 2022, then tumbled -58450bps in 2023.
  • Vivos Therapeutics' EBT Margin stood at 168.67% in 2021, then surged by 368bps to 452.05% in 2022, then crashed by -129bps to 132.45% in 2023, then surged by 42bps to 76.45% in 2024, then dropped by -4bps to 79.61% in 2025.
  • Per Business Quant, the three most recent readings for VVOS's EBT Margin are 79.61% (Q3 2025), 131.23% (Q2 2025), and 128.12% (Q1 2025).